- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.01. | NICE recommends wider use of Biogen MS drug via NHS | ||
| 02.01. | China delivers a win for Novo Nordisk on semaglutide IP | ||
| 02.01. | FDA declines to approve Corcept's rare disorder drug | ||
| 02.01. | Genmab ends lung cancer drug development | ||
| 31.12.25 | Vanda ends 40-year hiatus for new motion sickness drugs | ||
| 31.12.25 | Insilico ends 2025 with $293m Hong Kong IPO | ||
| 30.12.25 | Ultragenyx, Mereo's brittle bone drug flames out in trials | ||
| 30.12.25 | Judge blocks HHS' 340B rebate pilot at 11th hour | ||
| 29.12.25 | J&J abandons trial of atopic dermatitis drug | ||
| 29.12.25 | No Christmas present for Sanofi, as FDA turns down MS drug | ||
| 29.12.25 | Biosimilars unlock use of bevacizumab in bowel cancer by NHS | ||
| 24.12.25 | CMS aims for broader GLP-1 access via federal programmes | ||
| 24.12.25 | Sanofi swoops on Dynavax with $2.5bn takeover deal | ||
| 23.12.25 | Trump raises spectre of drug pricing mandates for Medicare | ||
| 23.12.25 | Novo Nordisk gets FDA okay for Wegovy pill | ||
| 22.12.25 | Andexxa reaches the end of the line in the US | ||
| 22.12.25 | Ipsen licenses Simcere ADC in $1bn-plus deal | ||
| 22.12.25 | AZ's ATR inhibitor ceralasertib flunks lung cancer test | ||
| 22.12.25 | Nine more companies sign pricing deals with Trump | ||
| 22.12.25 | BioMarin ends year with $4.8bn play for Amicus | ||
| 19.12.25 | US BIOSECURE Act passed by Congress | ||
| 18.12.25 | CEPI steps in to fund Moderna's pandemic flu jab | ||
| 18.12.25 | Ambros' $125m for pain disorder drug, and other financings | ||
| 18.12.25 | J&J's subcutaneous Rybrevant cleared by FDA | ||
| 18.12.25 | As year-end nears, pharma groups plump up their pipelines |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.